Source:http://linkedlifedata.com/resource/pubmed/id/19247179
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-3-12
|
| pubmed:abstractText |
The aim of this study was to evaluate the efficacy and safety of biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX regimen) in elderly patients with advanced gastric cancer (AGC). Forty-six eligible patients older than 65 years with previously untreated AGC received oxaliplatin 85 mg/m intravenously over a 2-h period on day 1, together with leucovorin 400 mg/m over 2 h, followed by a 46-h infusion of 5-fluorouracil 2600 mg/m every 2 weeks. All patients were evaluable for efficacy and toxicity. A median of seven cycles (range 1-12) was administered. The overall response rate was 45.6% [95% confidence interval (CI): 31-61%] with two complete responses, 19 partial responses, 15 stable diseases, and 10 progressions. Median time to progression was 6.2 months (95% CI: 4.6-7.8) and median overall survival was 9.8 months (95% CI: 8.2-11.4). Toxicity was fairly mild. Grade 3 toxicities included neutropenia (8.7%), nausea (4.3%), vomiting (4.3%), diarrhea (2.2%); and grade 4 toxicities occurred in none of the patients. Grades 1-2 peripheral neuropathy was reported in 43.5% of patients. The modified FOLFOX regimen is active, well tolerated as first-line chemotherapy for elderly patients aged above 65 years with AGC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1473-5741
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
281-6
|
| pubmed:meshHeading |
pubmed-meshheading:19247179-Age Factors,
pubmed-meshheading:19247179-Aged,
pubmed-meshheading:19247179-Aged, 80 and over,
pubmed-meshheading:19247179-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19247179-Disease Progression,
pubmed-meshheading:19247179-Drug Administration Schedule,
pubmed-meshheading:19247179-Female,
pubmed-meshheading:19247179-Fluorouracil,
pubmed-meshheading:19247179-Follow-Up Studies,
pubmed-meshheading:19247179-Gastrointestinal Diseases,
pubmed-meshheading:19247179-Humans,
pubmed-meshheading:19247179-Infusions, Intravenous,
pubmed-meshheading:19247179-Leucovorin,
pubmed-meshheading:19247179-Male,
pubmed-meshheading:19247179-Neutropenia,
pubmed-meshheading:19247179-Organoplatinum Compounds,
pubmed-meshheading:19247179-Peripheral Nervous System Diseases,
pubmed-meshheading:19247179-Stomach Neoplasms,
pubmed-meshheading:19247179-Survival Rate,
pubmed-meshheading:19247179-Treatment Outcome
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
|
| pubmed:affiliation |
Department of Oncology, Shaoxing People's Hospital, China.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|